[Intracerebral hemorrhage and treatment with platelet aggregation inhibitors: study of 21 cases].
BACKGROUND
The place of platelet antiaggregants in the aetiology of intracerebral hemorrhage (IH) has not been extensively studied.


OBJECTIVE
To analyze the characteristics of IH in patients treated with platelet antiaggregants and the possible clinical and prognostic differences from other primary IH.


METHODS
A retrospective study of patients admitted to hospital with primary IH from 1985 to 1997. The cases were IH patients while being treated with platelet antiaggregants. For each case we selected two controls with IH and similar age and IH risk factors. The following data was analyzed: start of clinical condition; type, dose, indication and duration of treatment with antiaggregants; mortality, localization, volume and extension of IH to the ventricles. The last four variables were compared with the control group using the ji squared test (chi 2) and the t student test.


RESULTS
21one patients had a primary IH while being treated with antiaggregants: 20 with salicylates (17 aspirin and 3 riflusal) and one with ticlopidine. The dose of aspirin was 500 mg or less in 90% of the cases. In the group treated with salicylates, this was given for more than 20 months in 90% of the cases. Initially there was no clinical progression in any case. No significant differences were observed between the variable compared, although there was a tendency to greater volume, extension to the ventricles and mortality in the group treated with antiaggregants.


CONCLUSIONS
More studies with larger numbers of patients are necessary to be able to confirm the tendencies observed.
Arjona
A
A
Servicio de Neurología, Clínica Puerta de Hierro, Madrid, España.
Bartolomé
M T
MT
Zabala
J A
JA
Millán
I
I
D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000009:adverse effects; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012459:Salicylates / Q000009:adverse effects
D010975:Platelet Aggregation Inhibitors; D012459:Salicylates; C016167:triflusal; D001241:Aspirin